0001209191-23-010558.txt : 20230217 0001209191-23-010558.hdr.sgml : 20230217 20230217161442 ACCESSION NUMBER: 0001209191-23-010558 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230215 FILED AS OF DATE: 20230217 DATE AS OF CHANGE: 20230217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pitman Jama CENTRAL INDEX KEY: 0001852595 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 23642704 MAIL ADDRESS: STREET 1: C/O DECIPHERA PHARMACEUTICALS, INC. STREET 2: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-15 0 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001852595 Pitman Jama C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET WALTHAM MA 02451 0 1 0 0 See Remarks Common Stock 2023-02-15 4 A 0 11151 0.00 A 46209 D Common Stock 2023-02-16 4 S 0 1159 15.099 D 45050 D Stock Option (Right to Buy) 15.48 2023-02-15 4 A 0 44600 0.00 A 2033-02-14 Common Stock 44600 44600 D The reporting person was awarded 11,151 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2024, February 15, 2025 and February 15, 2026. This sale was to cover tax liabilities in the vesting of restricted stock. This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2023. Title: SVP, Regulatory, Quality, & Portfolio Management /s/ Jeffrey M. Held, Attorney-in-Fact 2023-02-17